ZBIO Zenas BioPharma, Inc.

$31.12▲ +0.06% Healthcare Other
After hours $31.12▲ +0.00% Sep 11, 7:30 PM ET
Volume 421.7K Avg Volume (10D) 525.7K
Key Metrics & Fundamentals
Market Cap
$2.03B
P/E Ratio
–
Div Yield
–%
52W Range
13.50 - 44.60
% vs 50 MA
0.25%
% vs 200 MA
20.12%
RSI-14
47.2
MACD Histogram
-0.2600
Beta (1Y vs SPY)
0.89
Free Cash Flow
-$87.24M
Gross Rev
$1.00M
Gross Profit
$1.00M
EBITDA
-$71.04M
COGS
–
Operating Exp
$78.66M
Operating Income
-$77.66M
EBIT
-$77.66M
Pretax Income
-$111.34M
Net Income
-$111.46M
EPS (Diluted)
-1.77
Price & Volume History
Loading chart…
Recent News
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
GlobeNewswire · Sep 8, 2026 11:05 AM
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire · Sep 4, 2026 11:05 AM
Fortune Brands and 4 More Stocks See Action From Activist Investors
Barrons.com · Aug 28, 2026 11:46 PM
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Aug 18, 2026 8:15 PM
Zenas BioPharma's Q2 Net Loss Widens; CFO to Step Down
MT Newswires · Aug 13, 2026 11:30 AM
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · Aug 13, 2026 11:00 AM
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
MT Newswires · Jul 17, 2026 12:13 PM
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
Insider Monkey · Jul 10, 2026 1:58 PM
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
Motley Fool · Jun 21, 2026 11:31 AM
Financial Overview - Income Statement Quarterly

See ZBIO's money flow as a full page

Social Sentiment
Avg +0.60 · 2 posts
NewsDiscussionTradeWas bullish on ZBIO trial results, Wall Street was more bullish
r/wallstreetbets · Jan 5, 2026
The author expresses initial bullishness and later a negative sentiment due to loss of savings, indicating a generally positive initial view mixed with disappointment.
positive +0.60
Zenas Biopharma (ZBIO)
r/stocks · Nov 25, 2024
The post highlights positive trial data, insider buying, and potential for significant growth, indicating a bullish sentiment.
positive +0.60
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙